A Phase 2/3 interventional study of GlucoTab and Insulin Degludec in Type 2 Diabetes Mellitus, sponsored by Insel Gruppe AG, University Hospital Bern. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-16.
Sponsored by Insel Gruppe AG, University Hospital Bern · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 67th largest by enrollment, is one of 5 that started in 2018, is the only one in phase 2/3, and was the 59th registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Insel Gruppe AG, University Hospital Bern is the lead sponsor of 742 studies on the registry; 180 are open to participants now.
Insel Gruppe AG, University Hospital Bern has 4 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The GlucoTab® system is a computerized decision support system built of an android based front-end user interface and a backend server including the REACTION algorithm. GlucoTab® is able to process blood glucose data and physiological confounders of glycaemia. Subsequently, GlucoTab® provides patient-specific basal, bolus, and correction insulin doses together with visualization and documentation of relevant data. The GlucoTab® system was found capable to keep hospitalized diabetic patients in the recommended target range without increasing the risk for hypoglycaemic events. Insulin pharmacokinetic is a critical confounder of glycaemic variability and the main determinant of an algorithm-based decision support-system. GlucoTab® is intended for being used with a basal/bolus insulin regimen. Up to date, feasibility data are limited to the use of insulin glargine.
Insulin degludec, an ultra-long acting basal insulin is characterized by a stable pharmacokinetic profile a half-life of \~25 hours. It was found equally effective to insulin glargine with respect to glycaemic control, while the incidence of (nocturnal) hypoglycaemia was smaller in patients treated with insulin degludec. Within the present study, insulin glargine will be replaced by insulin degludec, which is not yet approved for dose titration with GlucoTab®.
In the present study, 15 non-critically ill T2DM patients, who were hospitalized at the University Clinic of Neurosurgery for various reasons and require insulin treatment will be recruited. Patients will be treated with insulin Tresiba and insulin Novorapid. For a maximum duration of 21 days, GlucoTab® will calculate the required insulin doses for each patient, depending on fasting plasma glucose and postprandial glucose measurements during the day. After the calculated Insulin dose has been approved by the physician, the nursing staff will give the dose to the respective patient.
The present study will analyse the efficacy of GlucoTab® for glycaemic management in T2DM patients using insulin degludec.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Recruited patients will be treated with insulin degludec and insulin aspart. insulin doses will be calculated by the GlucoTab system
Device: GlucoTab · Drug: Insulin Degludec
The GlucoTab® system is a computerized decision support system built of an android based front-end user interface and a backend server including the REACTION algorithm. GlucoTab® is able to process blood glucose data and physiological confounders of glycaemia. Subsequently, GlucoTab® provides patient-specific basal, bolus, and correction insulin doses together with visualization and documentation of relevant data. Insulin doses of recruited patients will be calculated by the GlucoTab System for at least 48 hours and a maximum duration of 21 days.
During the study, patients will be treated with basal Insulin degludec
Blood Glucose in target range in percent
We measure mean percentage of blood glucose measurements in the target range of ≥5.6 mmol/l ≤7.8 mmol/l.
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Random blood glucose <9.9 mmol/l in percent
We measure random daily blood glucose concentrations \<9.9 mmol/l as calculated by all pre-prandial and bedtime glucose values measured ≥24 hours after start of insulin therapy
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Number of severe hypoglycaemic episodes (defined as symptomatic or asymptomatic hypoglycaemia requiring third party help)
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Number of overall hypoglycaemic episodes defined as any measurement of capillary glucose concentrations ≤3.9 mmol/l with or without symptoms related to low blood glucose, according to the current definition of the American Diabetes Association (ADA)
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Number of blood glucose measurements per day
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Number of missed blood glucose measurements
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Number of additionally required blood glucose measurements
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Correction factor insulin dose per day
As calculated by GlucoTab
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Basal factor insulin dose per day
As calculated by GlucoTab
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Bolus insulin dose per day
As calculated by GlucoTab
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Number of insulin injections per day
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Number and reasons for non-performance of insulin injections per day
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Adherence to the insulin dose suggestion of the GlucoTab® system
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Mean daily blood glucose as calculated by pre-meal and bedtime blood glucose values: Overall and per treatment day
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Mean pre-bedtime blood glucose
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Mean pre-breakfast blood glucose
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Mean pre-lunch blood glucose
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Mean pre-dinner blood glucose
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Blood glucose <2.2 mmol/l in percent
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Blood glucose between 2.201-<3.9 mmol/l in percent
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Blood glucose between 3.901-<5.5 mmol/l in percent
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Blood glucose between 5.501- <7.8 mmol/l in percent
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Blood glucose between 7.801-< 9.9 mmol/l in percent
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Blood glucose between 9.901-<16.6 mmol/l in percent
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Blood glucose ≥16.601 mmol/l in percent
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Time of glucose measurements derived from CGM in the following ranges: 0-<2.2 mmol/l, 2.201-<3.9 mmol/l, 3.901-<5.5 mmol/l, 5.501-<7.8 mmol/l, 7.801-<9.9 mmol/l, 9.901-<16.6 mmol/l, ≥16.601 mmol/l
Time frame: during the treatment period (at least 48 hours but maximal 21 days per patient)
Plan to share: No
Ran from Jan 2018 to primary completion in Jan 2020, 24 months.
Of 26 non-industry phase 2/3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 30. This study's 24 months is above that.
Counting every sponsor, half of 32 studies reached it within 22 months; a quarter within 13 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin degludec
Insel Gruppe AG, University Hospital Bern →